Street Calls of the Week
Investing.com - TD Cowen has reiterated its Buy rating on Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a price target of $60.00, citing impressive commercial execution of its Arcalyst drug. The stock, currently trading near its 52-week high of $39.43, has delivered remarkable returns with a 93% gain over the past six months. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $44 to $60.
The firm anticipates Kiniksa will beat third-quarter 2025 expectations with estimated Arcalyst sales of $170 million, representing 8% quarter-over-quarter and 51% year-over-year growth, exceeding the consensus estimate of $166 million.
TD Cowen attributes the projected outperformance to Kiniksa’s growing prescriber base, increased market penetration, and favorable depth of prescribing for Arcalyst.
The research firm projects that these positive factors could result in accelerating growth for Kiniksa, estimating 2025 Arcalyst sales will reach $645 million, representing 55% year-over-year growth.
This sales projection slightly exceeds the high end of Kiniksa’s own guidance range of $625-640 million for Arcalyst in 2025, suggesting potential for the company to raise its full-year outlook.
In other recent news, Kiniksa Pharmaceuticals reported strong financial results for the second quarter of 2025, with net revenue increasing by 52% year-over-year to $156.8 million. This growth is attributed to the company’s strategic emphasis on its flagship product, ARCALYST, and an expanding clinical portfolio. Additionally, the U.S. Food and Drug Administration granted Orphan Drug Designation to Kiniksa’s treatment for pericarditis, KPL-387. This designation is significant for the company’s development of KPL-387, which is a monoclonal antibody aimed at treating recurrent pericarditis. These recent developments reflect Kiniksa’s ongoing efforts to enhance its product offerings and expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.